
1 / 4Oral Research Compounds
$264.00$105.60Save 60%
Quantity
$264.00$105.60
Orforglipron is a small-molecule, non-peptide GLP-1 receptor agonist that appears in published literature examining GLP-1 receptor binding and incretin pathway signaling. It is catalogued alongside research peptides because of the receptor it targets, though structurally it is a synthetic small molecule rather than a peptide chain, which is why it is studied in an orally administered capsule format in laboratory settings.
This listing supplies Orforglipron as capsules in a 90-count bottle, finished in the USA. Every batch is tested by an independent third-party laboratory, and the certificate for the current lot is published on the lab results pages so it can be reviewed before purchase. Orders ship from facilities in Florida and California within 24 hours. Sold strictly for laboratory research use only.
Orforglipron Capsules · 12mg(60 capsules)
$105.60$264.00
Recommended with this order
Frequently paired with this compound by other researchers.
Lab results · certificate of analysis
Every node is a test the laboratory ran on this batch — read straight off this product's certificate in our COA registry. Tap a node for the standard it had to meet and the result that came back.
Purity
99.449%
Average purity across the conformity vials pulled from this batch, by HPLC. The per-vial figures print further down the certificate.
hover to hold · tap a node for the standard and the result
For Research Use Only. Not for human or veterinary use. Not for use in diagnostic or therapeutic procedures. Not for food, drug, or cosmetic use.
99% Pure | 90 Capsules | Finished in the USA
Orforglipron is a small-molecule, non-peptide GLP-1 receptor agonist. It appears in published research examining GLP-1 receptor binding and incretin pathway signaling — notable for achieving receptor engagement without a peptide backbone.
For Research Use Only. Not for human or veterinary use.

Orforglipron is a small-molecule GLP-1 receptor agonist. It is not a peptide — which is precisely what makes it a research subject. Most compounds engaging the GLP-1 receptor are peptide-based, and achieving comparable receptor activity with a small molecule represents a distinct pharmacological approach.
Published research examines Orforglipron in receptor binding assays and in comparative work against peptide-based incretin compounds.


Oral Research Compounds compounds
Research library